recombinate 250 iu powder and solvent for solution for injection
baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - octocog alfa - powder and solvent for solution for injection - octocog alfa 25 iu/ml - antihemorrhagics
recombinate 500iu powder and solvent for solution for injection
baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - octocog alfa - powder and solvent for solution for injection - octocog alfa 500 iu - antihemorrhagics
recombinate 1000iu powder and solvent for solution for injection
baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - octocog alfa - powder and solvent for solution for injection - octocog alfa 1000 iu - antihemorrhagics
feiba 50units/ml (1,000unit) powder and 20ml solvent for solution for infusion vials
1,000unit) powder and 20ml solvent for solution for infusion vials (takeda uk ltd - factor viii inhibitor bypassing fraction - powder and solvent for solution for infusion - 1000unit
feiba 25 u/ml powder and solvent for solution for infusion
baxalta innovations gmbh - feiba - powder and solvent for solution for infusion - 25 unit(s)/millilitre - blood coagulation factors; factor viii inhibitor bypassing activity - coagulation factors - it is used for: treatment of bleeding in hemophilia a patients with inhibitors; treatment of bleeding in hemophilia b patients with inhibitors, if no other specific treatment is available (see section 5.1); treatment of bleeding in non-hemophiliacs with acquired inhibitors to factor viii; prophylaxis of bleeding in hemophilia a patients with inhibitors who have experienced a significant bleed or are at high risk of significant bleeding
feiba 50 u/ml powder and solvent for solution for infusion
baxalta innovations gmbh - feiba - powder and solvent for solution for infusion - 50 unit(s)/millilitre - blood coagulation factors; factor viii inhibitor bypassing activity - blood coagulation factors - it is used for: treatment of bleeding in hemophilia a patients with inhibitors; treatment of bleeding in hemophilia b patients with inhibitors, if no other specific treatment is available (see section 5.1); treatment of bleeding in non-hemophiliacs with acquired inhibitors to factor viii; prophylaxis of bleeding in hemophilia a patients with inhibitors who have experienced a significant bleed or are at high risk of significant bleeding
feiba 50 u/ml powder and solvent for solution for infusion
baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - powder and solvent for solution for infusion - factor viii inhibitor bypassing fraction 50 u/ml - antihemorrhagics
feiba 100 u/ml powder and solvent for solution for infusion (500 u/5 ml)
baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - powder and solvent for solution for infusion - factor viii inhibitor bypassing fraction 100 u/ml - antihemorrhagics
feiba 100 u/ml powder and solvent for solution for infusion (1000 u/10 ml)
baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - powder and solvent for solution for infusion - factor viii inhibitor bypassing fraction 100 u/ml - antihemorrhagics
medicinal product name : feiba 100 u/ml powder and solvent for solution for infusion (2500 u/25 ml)
baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - powder and solvent for solution for infusion - factor viii inhibitor bypassing fraction 100 u/ml - antihemorrhagics